trending Market Intelligence /marketintelligence/en/news-insights/trending/NPBHG3YMivtOXHcZeBuAaQ2 content esgSubNav
In This List

Axim Biotechnologies to acquire oncology research company Sapphire Biotech

Blog

Insight Weekly: M&A outlook; US community bank margins; green hydrogen players' EU expansion

Blog

Global M&A by the Numbers: Q2 2022

Blog

Insight Weekly: US bank M&A; low refinancing eases rates impact; Texas crypto mining booms

Blog

Infographic 2022 Top Tech Trends Shaping Corporations


Axim Biotechnologies to acquire oncology research company Sapphire Biotech

Axim Biotechnologies Inc. signed a binding term sheet to acquire Sapphire Biotech Inc., an oncology research and development company.

Sapphire develops proprietary therapies for inhibiting growth and spread of cancer. The company is also developing diagnostics for early cancer detection, response to treatment and recurrence monitoring.

As part of the agreement, San Diego-based Axim Biotechnologies will acquire all of Sapphire's outstanding capital and assume all its outstanding debt.

The parties plan to enter into a definitive deal by Feb. 28.

Axim will gain Sapphire's portfolio of technologies through the deal, as well as the ability to develop new proprietary molecules, the company said in a filing.

Axim develops and produces cannabinoid-based pharmaceutical and nutraceutical products.